Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
20.36
-0.12 (-0.59%)
Nov 20, 2024, 4:00 PM EST - Market closed
Bicycle Therapeutics Employees
Bicycle Therapeutics had 284 employees as of December 31, 2023. The number of employees increased by 48 or 20.34% compared to the previous year.
Employees
284
Change (1Y)
48
Growth (1Y)
20.34%
Revenue / Employee
$129,923
Profits / Employee
-$585,479
Market Cap
1.41B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Evolent Health | 4,700 |
InMode | 581 |
BioCryst Pharmaceuticals | 536 |
Intellia Therapeutics | 526 |
Travere Therapeutics | 380 |
Kiniksa Pharmaceuticals International, | 297 |
Nurix Therapeutics | 284 |
Ocular Therapeutix | 267 |
BCYC News
- 9 days ago - Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference - Business Wire
- 14 days ago - Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern - Seeking Alpha
- 19 days ago - Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Business Wire
- 4 weeks ago - Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals - Business Wire
- 5 weeks ago - Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress - Business Wire
- 2 months ago - Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024 - Business Wire
- 2 months ago - Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone - Benzinga